Bolt Biotherapeutics, Inc.
BOLT
$3.68
-$0.18-4.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -99.72% | -97.87% | -- | 90.10% | 41.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.72% | -97.87% | -- | 90.10% | 41.49% |
| Cost of Revenue | -31.33% | -50.11% | -57.45% | -52.59% | -51.42% |
| Gross Profit | 9.66% | 42.79% | 78.77% | 65.47% | 59.78% |
| SG&A Expenses | -31.11% | -26.85% | -21.03% | -12.16% | -27.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.26% | -42.81% | -48.27% | -43.86% | -45.76% |
| Operating Income | 17.85% | 37.26% | 64.23% | 53.15% | 51.61% |
| Income Before Tax | 9.82% | 34.38% | 58.39% | 52.93% | 59.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.82% | 34.38% | 58.39% | 52.93% | 59.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.82% | 34.38% | 58.39% | 52.93% | 59.61% |
| EBIT | 17.85% | 37.26% | 64.23% | 53.15% | 51.61% |
| EBITDA | 16.56% | 36.86% | 64.90% | 53.68% | 52.29% |
| EPS Basic | -2.29% | 25.15% | 53.88% | 53.09% | 59.84% |
| Normalized Basic EPS | 8.42% | 25.15% | 61.14% | 53.09% | 51.72% |
| EPS Diluted | -2.29% | 25.15% | 53.88% | 53.09% | 59.84% |
| Normalized Diluted EPS | 8.42% | 25.15% | 61.14% | 53.09% | 51.72% |
| Average Basic Shares Outstanding | -11.84% | -12.34% | -9.77% | 0.36% | 0.58% |
| Average Diluted Shares Outstanding | -11.84% | -12.34% | -9.77% | 0.36% | 0.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |